A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study Comparing Relative Efficacy of CE Budesonide+Azelastine and Rhinocort Aqua+Astelin Nasal Sprays Against Placebo in the Treatment of AR in an EEC Model.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study Comparing Relative Efficacy of CE Budesonide+Azelastine and Rhinocort Aqua+Astelin Nasal Sprays Against Placebo in the Treatment of AR in an EEC Model.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2012

At a glance

  • Drugs Budesonide/azelastine (Primary) ; Azelastine; Budesonide
  • Indications Hypersensitivity; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors CyDex Pharmaceuticals
  • Most Recent Events

    • 05 Aug 2012 Company (Ligand Pharmaceuticals) added as reported by ClinicalTrials.gov.
    • 05 Nov 2009 Quality of life reported at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI).
    • 18 Jul 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, record no. NCT00940953).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top